828 related articles for article (PubMed ID: 25629741)
1. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
Mesa R; Vannucchi AM; Yacoub A; Zachee P; Garg M; Lyons R; Koschmieder S; Rinaldi C; Byrne J; Hasan Y; Passamonti F; Verstovsek S; Hunter D; Jones MM; Zhen H; Habr D; Martino B
Br J Haematol; 2017 Jan; 176(1):76-85. PubMed ID: 27858987
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for the treatment of patients with polycythemia vera.
Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
6. Low-dose ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis.
Islam R; Yellu MR; Rafiullah ; Shaw GR
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23704469
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Harrison CN; Nangalia J; Boucher R; Jackson A; Yap C; O'Sullivan J; Fox S; Ailts I; Dueck AC; Geyer HL; Mesa RA; Dunn WG; Nadezhdin E; Curto-Garcia N; Green A; Wilkins B; Coppell J; Laurie J; Garg M; Ewing J; Knapper S; Crowe J; Chen F; Koutsavlis I; Godfrey A; Arami S; Drummond M; Byrne J; Clark F; Mead-Harvey C; Baxter EJ; McMullin MF; Mead AJ
J Clin Oncol; 2023 Jul; 41(19):3534-3544. PubMed ID: 37126762
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
Palandri F; Auteri G; Abruzzese E; Caocci G; Bonifacio M; Mendicino F; Latagliata R; Iurlo A; Branzanti F; Garibaldi B; Trawinska MM; Cattaneo D; Krampera M; Mulas O; Martino EA; Cavo M; Vianelli N; Impera S; Efficace F; Heidel F; Breccia M; Elli EM; Palumbo GA
Ann Hematol; 2024 Jun; 103(6):1931-1940. PubMed ID: 38478023
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
Haematologica; 2013 Dec; 98(12):1865-71. PubMed ID: 24038026
[TBL] [Abstract][Full Text] [Related]
12. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
Chojecki A; Boselli D; Dortilus A; Hamadeh I; Begley S; Chen T; Bose R; Podoltsev N; Zeidan AM; Balmaceda NB; Yacoub A; Ai J; Knight TG; Ragon BK; Shah NA; Sanikommu SR; Symanowski J; Mesa R; Grunwald MR
Ann Hematol; 2024 Apr; ():. PubMed ID: 38662203
[TBL] [Abstract][Full Text] [Related]
13. [The relationship between symptom burden and hematologic responses after treatment with interferon/hydroxyurea in patients with polycythemia vera].
Liu D; Xu ZF; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):635-641. PubMed ID: 34547868
[No Abstract] [Full Text] [Related]
14. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera.
Masarova L; Chifotides HT
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):141-148. PubMed ID: 38135633
[TBL] [Abstract][Full Text] [Related]
15. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract][Full Text] [Related]
16. Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.
Zeitler K; Jariwala R; Alrabaa S; Sriaroon C
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34725058
[TBL] [Abstract][Full Text] [Related]
17. Unexpected Neurological Symptoms of Ruxolitinib: A Case Report.
Furia F; Canevini MP; Federici AB; Carraro MC
J Hematol; 2020 Dec; 9(4):137-139. PubMed ID: 33224394
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation.
Dold L; Lutz P; Heine A; Weismüller TJ; Strassburg CP; Spengler U
Clin Case Rep; 2021 Sep; 9(9):e04782. PubMed ID: 34504700
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
